At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 142 enrolled
Drug / intervention
Apilimod Dimesylate Capsule +1 moredrug
Likely dose
Apilimod Dimesylate Capsule 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19
In Brief
A Phase 2 clinical trial evaluating Apilimod Dimesylate Capsule and Placebo for COVID-19 Disease. Completed, enrolled 142 participants across 1 site.
Detailed Summary
This is a clinical trial to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standards supportive care in an outpatient setting.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19 Disease
CountriesUnited States
CollaboratorsYale University
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2020
Primary CompletionMar 2021
Study CompletionApr 2021
TodayJul 2026
First PostedJun 24, 2020
Enrollment StartJul 15, 2020
Primary CompletionMar 24, 2021
Study CompletionApr 19, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.0 years ago
Interventions
Apilimod Dimesylate Capsuledrug
LAM-002A is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, Size 0.
Placeboother
Microcrystalline cellulose in Swedish orange, Size 0 capsules